IDEXX Laboratories, Inc. $IDXX is TimesSquare Capital Management LLC’s 6th Largest Position

TimesSquare Capital Management LLC lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.1% in the third quarter, HoldingsChannel.com reports. The firm owned 192,938 shares of the company’s stock after selling 8,338 shares during the quarter. IDEXX Laboratories comprises 1.8% of TimesSquare Capital Management LLC’s holdings, making the stock its 6th largest position. TimesSquare Capital Management LLC’s holdings in IDEXX Laboratories were worth $123,266,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. J.Safra Asset Management Corp acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $31,000. Armstrong Advisory Group Inc. lifted its stake in IDEXX Laboratories by 55.9% during the third quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock worth $34,000 after purchasing an additional 19 shares during the last quarter. Salomon & Ludwin LLC acquired a new position in IDEXX Laboratories in the third quarter valued at approximately $35,000. Greykasell Wealth Strategies Inc. purchased a new position in IDEXX Laboratories in the third quarter valued at approximately $35,000. Finally, WealthCollab LLC acquired a new stake in IDEXX Laboratories during the 2nd quarter worth $30,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $629.35 on Friday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The company’s 50-day moving average price is $684.99 and its 200 day moving average price is $667.68. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $769.98. The stock has a market cap of $50.25 billion, a price-to-earnings ratio of 48.15, a PEG ratio of 3.83 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the company earned $2.53 earnings per share. The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. BTIG Research reduced their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a report on Monday, November 3rd. JPMorgan Chase & Co. upped their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Piper Sandler reduced their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $830.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Seven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $783.33.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP George Fennell sold 11,345 shares of the company’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total value of $7,337,038.40. Following the transaction, the executive vice president directly owned 9,823 shares in the company, valued at approximately $6,352,730.56. This represents a 53.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.